🔎 Trials Near Me

Utama › Kanser Saluran Pernafasan › Texas

Kajian klinikal Kanser Saluran Pernafasan di Texas

5 kajian untuk Kanser Saluran Pernafasan sedang mencari peserta di lokasi di Texas.

Bandar di Texas

Teks kajian rasmi (Bahasa Inggeris)

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • MD Anderson, Houston
  • NEXT Dallas, Irving
  • NEXT Oncology San Antonio, San Antonio
  • dan 1 lagi
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06128551

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • USO - Texas Oncology, Austin
  • William Beaumont Army Medical Center, Fort Bliss
  • Houston Methodist Hospital, Houston
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  • Texas Oncology, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Sep 2026 · NCT07185997

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • UT Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Feb 2026 · NCT02984761

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.